Quotient Ltd: restructuring charge — Quotient reaches restructuring deal: equity wiped out for no consideration, delisting from Nasdaq, 100 job cuts

Quotient Ltd

All existing ordinary shares, options, warrants to be extinguished and cancelled for no consideration; delisting from Nasdaq planned.
Senior secured noteholders to provide $10M bridge notes; exchange existing notes for new senior secured debt at discount.
Convertible notes to be extinguished for no value; holders may purchase $28M in new common equity at 35% discount.
Workforce reduction of ~100 positions as company shifts from transfusion diagnostics to autoimmune/allergy MosaiQ products.
Company estimates $1.5-2.5M in pre-tax severance costs; majority paid in Q1-Q2 2023.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Quotient Ltd announced a restructuring with charges of between $1.5 million to $2.5 million affecting transfusion diagnostics products commercialization (by approximately 100 positions).

Type: restructuring
Charge: between $1.5 million to $2.5 million
Affected area: transfusion diagnostics products commercialization
Headcount: by approximately 100 positions

Exact text from the filing

As indicated in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2022, filed November 14, 2022, the board of directors of the Company has approved a change in strategy in which the Company would suspend its activities focused on the commercialization of its transfusion diagnostics products and would instead focus in the near term on development and commercialization of MosaiQ products for the autoimmune and allergy clinical diagnostics markets. As a result of this shift in strategy, the Company will implement a material reduction in its workforce by approximately 100 positions. The Company estimates that it will incur aggregate pre-tax charges of between $1.5 million to $2.5 million.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-22-300271

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.